The Alliance
This is a public-private collaboration agreement between SSPA and Roche in a network that is comprised of a monitoring commission and a scientific committee for the development of a scientific programme in which three research groups from the SSPA participate, made up of Medical Oncologists, Biologists, Pharmacists, Biotechnologists, Laboratory Technicians, Managers, etc. They belong to the IBIMA research group led by Emilio Alba, the IMIBIC research group led by Enrique Aranda and the IBIS research group led by Javier Salvador, with the collaboration of Roche Farma and FPS.
A multidisciplinary team including more than 40 professionals has embarked upon this Alliance that aspires to consolidate and grow with a view to overcoming new challenges.
Scientific Committee
This will ensure scientific excellence and efficiency with regard to the Alliance’s research activity.
Emilio Alba
IR IBIMA Malaga
Javier Salvador
IR IBIS Seville
Enrique Aranda
IR IMIBIC Cordoba
Marta Reboredo
Director of Project Management Division
Progress and Health Foundation
María Pérez Martín
Alliance Manager
Progress and Health Foundation
María López
Medical Collaborations & Operations Expert
Roche
Saioa Alonso
Disease Area Leader Breast and Gyn Cancer
Roche
Monitoring Committee
This will monitor the collaboration agreement between Roche and FPS and ensure proper coordination of actions.
Gonzalo Balbotín
Managing Director FPS
Progress and Health Foundation
Enrique Aranda
Coordinating Researcher (Rotatory)
Andalusian Health Service
María Pérez Martín
Alliance Manager
Progress and Health Foundation
María López
Medical Collaborations & Operations Expert
Roche
José María Gómez
Regional HCS Leader
Roche
Jesús Herrera
Regional Access Partner
Roche
Research Team – Malaga Node
Group: “Clinical and translational research into cancer”
IR: Emilio Alba Conejo
Research Team – Seville Node
Group: “Molecular and Translational Research into Oncology”
IR: Javier Salvador Bofill
Co- IR: Reyes Bernabé and Sonia Molina-Pinelo
Research Team – Cordoba Node
Group: “New therapies in cancer”
IR: Enrique Aranda Aguilar
Co- IR: Antonio Rodríguez and Juan Rafael de la Haba
